BR9608407A - Use of a pharmaceutical preparation compound for use in the prophylaxis and / or treatment of multiple system organ failure and process for prophylaxis and treatment of multiple system organ failure in mammals including man - Google Patents
Use of a pharmaceutical preparation compound for use in the prophylaxis and / or treatment of multiple system organ failure and process for prophylaxis and treatment of multiple system organ failure in mammals including manInfo
- Publication number
- BR9608407A BR9608407A BR9608407A BR9608407A BR9608407A BR 9608407 A BR9608407 A BR 9608407A BR 9608407 A BR9608407 A BR 9608407A BR 9608407 A BR9608407 A BR 9608407A BR 9608407 A BR9608407 A BR 9608407A
- Authority
- BR
- Brazil
- Prior art keywords
- prophylaxis
- treatment
- multiple system
- organ failure
- system organ
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9501881A SE9501881D0 (en) | 1995-05-19 | 1995-05-19 | New pharmacological use of AII receptor antagonists |
| PCT/SE1996/000602 WO1996036336A1 (en) | 1995-05-19 | 1996-05-08 | New pharmacological use of aii-receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9608407A true BR9608407A (en) | 1998-12-29 |
Family
ID=20398385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9608407A BR9608407A (en) | 1995-05-19 | 1996-05-08 | Use of a pharmaceutical preparation compound for use in the prophylaxis and / or treatment of multiple system organ failure and process for prophylaxis and treatment of multiple system organ failure in mammals including man |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5900428A (en) |
| EP (1) | EP0830131A1 (en) |
| JP (1) | JPH11505243A (en) |
| KR (1) | KR19990014905A (en) |
| CN (1) | CN1093761C (en) |
| AU (1) | AU706301B2 (en) |
| BR (1) | BR9608407A (en) |
| CA (1) | CA2219395A1 (en) |
| CZ (1) | CZ290155B6 (en) |
| EE (1) | EE03666B1 (en) |
| HU (1) | HUP9900227A3 (en) |
| IL (1) | IL118299A (en) |
| IS (1) | IS4597A (en) |
| MX (1) | MX9708557A (en) |
| MY (1) | MY114428A (en) |
| NO (1) | NO975221L (en) |
| NZ (1) | NZ308260A (en) |
| RU (1) | RU2194505C2 (en) |
| SE (1) | SE9501881D0 (en) |
| SK (1) | SK151397A3 (en) |
| TW (1) | TW473389B (en) |
| WO (1) | WO1996036336A1 (en) |
| ZA (1) | ZA963569B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW580397B (en) * | 1997-05-27 | 2004-03-21 | Takeda Chemical Industries Ltd | Solid preparation |
| US6514249B1 (en) | 1997-07-08 | 2003-02-04 | Atrionix, Inc. | Positioning system and method for orienting an ablation element within a pulmonary vein ostium |
| SE9800550D0 (en) * | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| US6328994B1 (en) * | 1998-05-18 | 2001-12-11 | Takeda Chemical Industries, Ltd. | Orally disintegrable tablets |
| TWI257311B (en) * | 1998-07-28 | 2006-07-01 | Takeda Chemical Industries Ltd | Rapidly disintegrable solid preparation |
| PL356422A1 (en) | 2000-02-18 | 2004-06-28 | Takeda Chemical Industries, Ltd. | Tnf-alpha inhibitors |
| DE602005025755D1 (en) | 2004-06-04 | 2011-02-17 | Teva Pharma | IRBESARTAN PHARMACEUTICAL COMPOSITION CONTAINING |
| KR20130074808A (en) | 2011-12-16 | 2013-07-05 | 한올바이오파마주식회사 | The pharmaceutical composition comprising losartan for treating or preventing statin-induced muscle toxicity |
| CN104261284B (en) * | 2014-09-18 | 2016-02-03 | 中邮建技术有限公司 | A kind of antenna hanging apparatus of wireless base station |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| US5538991A (en) * | 1994-09-14 | 1996-07-23 | Merck & Co., Inc. | Endothelin antagonists bearing 5-membered heterocyclic amides |
-
1995
- 1995-05-19 SE SE9501881A patent/SE9501881D0/en unknown
-
1996
- 1996-05-06 ZA ZA963569A patent/ZA963569B/en unknown
- 1996-05-08 CZ CZ19973454A patent/CZ290155B6/en not_active IP Right Cessation
- 1996-05-08 KR KR1019970708250A patent/KR19990014905A/en not_active Application Discontinuation
- 1996-05-08 SK SK1513-97A patent/SK151397A3/en unknown
- 1996-05-08 CA CA002219395A patent/CA2219395A1/en not_active Abandoned
- 1996-05-08 BR BR9608407A patent/BR9608407A/en not_active Application Discontinuation
- 1996-05-08 AU AU57845/96A patent/AU706301B2/en not_active Ceased
- 1996-05-08 RU RU97120700/14A patent/RU2194505C2/en active
- 1996-05-08 WO PCT/SE1996/000602 patent/WO1996036336A1/en not_active Application Discontinuation
- 1996-05-08 US US08/696,971 patent/US5900428A/en not_active Expired - Fee Related
- 1996-05-08 JP JP8534742A patent/JPH11505243A/en active Pending
- 1996-05-08 NZ NZ308260A patent/NZ308260A/en unknown
- 1996-05-08 CN CN96193988A patent/CN1093761C/en not_active Expired - Fee Related
- 1996-05-08 HU HU9900227A patent/HUP9900227A3/en unknown
- 1996-05-08 EP EP96914504A patent/EP0830131A1/en not_active Withdrawn
- 1996-05-08 EE EE9700309A patent/EE03666B1/en not_active IP Right Cessation
- 1996-05-08 MX MX9708557A patent/MX9708557A/en not_active IP Right Cessation
- 1996-05-16 IL IL11829996A patent/IL118299A/en not_active IP Right Cessation
- 1996-05-18 MY MYPI96001899A patent/MY114428A/en unknown
- 1996-06-08 TW TW085106910A patent/TW473389B/en not_active IP Right Cessation
-
1997
- 1997-10-22 IS IS4597A patent/IS4597A/en unknown
- 1997-11-13 NO NO975221A patent/NO975221L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EE03666B1 (en) | 2002-04-15 |
| CA2219395A1 (en) | 1996-11-21 |
| RU2194505C2 (en) | 2002-12-20 |
| IL118299A (en) | 2000-07-26 |
| US5900428A (en) | 1999-05-04 |
| SK151397A3 (en) | 1998-08-05 |
| NZ308260A (en) | 2000-12-22 |
| AU5784596A (en) | 1996-11-29 |
| CN1184424A (en) | 1998-06-10 |
| IS4597A (en) | 1997-10-22 |
| EE9700309A (en) | 1998-06-15 |
| CN1093761C (en) | 2002-11-06 |
| AU706301B2 (en) | 1999-06-10 |
| WO1996036336A1 (en) | 1996-11-21 |
| CZ345497A3 (en) | 1998-03-18 |
| NO975221D0 (en) | 1997-11-13 |
| KR19990014905A (en) | 1999-02-25 |
| NO975221L (en) | 1997-11-13 |
| MY114428A (en) | 2002-10-31 |
| EP0830131A1 (en) | 1998-03-25 |
| JPH11505243A (en) | 1999-05-18 |
| HUP9900227A2 (en) | 2000-03-28 |
| HUP9900227A3 (en) | 2002-11-28 |
| ZA963569B (en) | 1996-11-19 |
| CZ290155B6 (en) | 2002-06-12 |
| MX9708557A (en) | 1997-12-31 |
| SE9501881D0 (en) | 1995-05-19 |
| IL118299A0 (en) | 1996-09-12 |
| TW473389B (en) | 2002-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9600821A (en) | Compound pharmaceutical formulation and process for the preparation of a compound | |
| BR9406566A (en) | Pharmaceutical composition use of progesterone and / or 17 - - estradiol and process for the manufacture of a pharmaceutical preparation | |
| BR9602705A (en) | Compound pharmaceutical composition process for the preparation of a compound and use | |
| BR9407720A (en) | Compound pharmaceutical composition and process for the prevention or treatment of immunoregulatory disorders or diseases that comprise the administration of the compound | |
| BR9407869A (en) | Combination of pharmaceutical composition and process for the treatment of osteoporosis | |
| BR9602856A (en) | Composition of polysaccharide grafted method for the treatment of arthritis in mammals and for the preparation of polysaccharide grafted with antioxidant | |
| BR9703624A (en) | Combination pharmaceutical formulation process for the treatment of depression in an animal use of mirtazapine use of one or more srri's and packaging | |
| PT98944A (en) | PROCESS FOR THE PREPARATION OF ALTERED ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFECTIONS | |
| BR9608405A (en) | Compound pharmaceutical composition and process for treating a patient suffering from a physiological disorder | |
| BR9408148A (en) | Process for the treatment of compound arrhythmia and pharmaceutical formulation | |
| BR9609780A (en) | Compound use of a compound process for the treatment of pharmaceutical composition conditions processes for preparing a pharmaceutical composition and for preparing a compound | |
| BR9605111A (en) | Oral pharmaceutical dosage formulation process for the manufacture of a fixed dosage formulation method for the treatment of disorders with helicobacter pylori infections in mammals and humans and use of a dosage formulation | |
| BR9302737A (en) | THIAZOLIVINYLPHENYL DERIVATIVES, PROCESS FOR THE PREPARATION OF A COMPOUND, MEDICATION, USE AND PROCESSES TO TREAT OR PREVENT BRONCHIC ASTHMA | |
| BR9601093A (en) | Pyrido (3,2-E) pyrazinoes process for its preparation medicines process for its preparation and use | |
| BR9505107A (en) | Compound pharmaceutical composition process for the preparation of a compound and its use | |
| BR9506581A (en) | Compound pharmaceutical composition use of the process compound for the prophylaxis or treatment of a clinical condition in a manifer for example a human and for the preparation of a compound and intermediate compound | |
| BR9708607A (en) | Compound pharmaceutical composition use of a compound process for treating or reducing the risk of inflammatory disease in a patient and for the preparation of a compound and chemical intermediate | |
| BR9502471A (en) | Guanidine compound Process for preparing a guanidine compound Pharmaceutical composition Use of a guanidine compound Method for the prophylactic or therapeutic treatment of diseases and process for preparing a pharmaceutical composition | |
| BR9607346A (en) | Compound use of a compound, pharmaceutical composition and process for the treatment of a mammal and for and preparation of compounds | |
| BR9608407A (en) | Use of a pharmaceutical preparation compound for use in the prophylaxis and / or treatment of multiple system organ failure and process for prophylaxis and treatment of multiple system organ failure in mammals including man | |
| BR9612281A (en) | Process for the preparation of a 1,2-bis (acyloxylate) and a 3,4-diacetoxy-1-butene | |
| BR9710376A (en) | Antiviral compound use of the same pharmaceutical composition and process for prophylactic or therapeutic antiviral treatment of a human or non-human animal | |
| BR9506098A (en) | Optically active compound process to produce the same osteogenesis promoter agent to prevent or treat bone disease promoter for bone fracture healing processes to promote osteogenesis and to prevent or treat bone disease in a mammal and use of an optically active compound | |
| BR9610733A (en) | Compound processes for the preparation of it and for the treatment of a mammal pharmaceutical composition and use of a compound | |
| BR9610316A (en) | Compound process for the production and use of the same process for the treatment of airway disease and pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EG | Technical examination (opinion): publication of technical examination (opinion) | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |